TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Tmax for Deferiprone and Deferiprone 3-O-glucuronide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T1/2 for Serum Deferiprone and Deferiprone 3-O-glucuronide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Overall Dry Skin Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in the Number of Operational Taxonomic Units (OTUS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Antibacterial Resistance Genes (ARG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Knee injury and Osteoarthritis Outcome Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Forgotten Joint Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change from baseline in ICF-CY evaluation form
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: change from baseline in Vineland Adaptive Behavior Scale II (VABS-II)
Endpoint domain: Life impact
Endpoint subdomain: Adaptive functioning
Primary endpoint: Accuracy level of the EarlySense system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Adverse Events and Dose Limiting Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Success of the technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boron uptake ratio in tumor vs normal tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: postoperative compensatory hyperhidrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in POSAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change From Baseline in Migraine Period Frequency Per 28 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of thromboembolic serious adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change of days of crying
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of average duration of evening crying
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of fecal calprotectin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: rate of diagnosis of meniscal abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean Sleep Latency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Successful isolation and ex-vivo expansion of MILs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of glabellar frown line severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hyperalgesic response to sunburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Objective clinical response (complete or partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate Clinical and Parasitological Response rate at Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cold test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in performance of a static balance task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in performance of an anticipatory balance task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in stride length when balance is challenged during gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Forced Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline distance covered in six-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time spent within the gestational diabetes glucose target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neonatal body fat%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulated changes in chloride transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kidney damage prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Quality of life of operated patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life associated to incontinence (Wexner incontinence score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life associated to incontinence (Faecal incontinence quality of life scale)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Best Gain in Best Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline daily steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline moderate physical activity minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline vigorous physical activity minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the King's Health Questionnaire (KHQ) Domain Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Subjects With Injection Site Adverse Experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Patient Reported Outcome for Pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: peri-operative mortality incidence rates
Endpoint domain: Mortality/survival
Primary endpoint: 7 Day Point Prevalence of Cigarette Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Radiolabeled lipid content in stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ED50 of Paracetamol, morphine and their combination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General Health Questionnaire-12
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Eczema Area and Severity Index (EASI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Gait analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Corneal Thickness at 1 Millimeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Corneal Thickness at 2 Millimeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in brain background rhythms after stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in resting state functional connectivity after stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in eye movement metrics for concussion detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: bone pain response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Bilirubin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete resolution of left atrial or left atrial appendage thrombus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under The Plasma Concentration Versus Time Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants not on glucose-lowering medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence of the A133S polymorphism of the RASSF1A tumor suppressor gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Acute rectal, bladder and other toxicity rates
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life measure - EORTC QLQ C-30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life measure - EPIC-26
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 6-hour Mortality
Endpoint domain: Mortality/survival
Primary endpoint: 30-days Mortality
Endpoint domain: Mortality/survival
Primary endpoint: small & dense LDL I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: non-HDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Amount of NSAIDs Used During 14 Days Prior to First Tocilizumab Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Amount of NSAIDs Used During 14 Days After 6-8 Weeks of Tocilizumab Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Amount of NSAIDs Used During 14 Days After 12-16 Weeks of Tocilizumab Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of patients affected with depression and anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Correlation between SPI value and heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correlation between Arterial waveform and Flotrac(TM) cardiac output analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Program Enrollment Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Program Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pharmacokinetics of oral dexamethasone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of oral hydrocortisone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative PaO2/FiO2 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of subjects using the device daily
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: COVID-19 test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Non-progression Rate (NPR) at 18 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Ingestible Event Marker (IEM) Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fitzpatrick wrinkle score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pleasure and enjoyment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma levels of theophylline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve from zero extrapolated to infinity (AUC0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (Cmax) for theophylline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Arginine production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean score of valence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IgG Anti-KLH Antibody Response Post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Electroencephalography Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amount of tissue micro-fragments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic tissue area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total tissue area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days until next prescription fill
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tumor perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-months prolonged smoking abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with complete cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Infant Stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Rosenberg's Self Esteem Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline United Parkinsons Disease Rating Scale Part III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline Fahn Tolosa Marin tremor scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to report Respiration Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Alcohol Related Consequences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Saving Inventory - Revised (SI-R)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Immune-inflammatory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Longitudinal cytokine measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-telomerase specific Th1 responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: VZV-specific cell mediated immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUC for mouth and throat soreness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visceral abdominal fat area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Microbiologically confirmed viral acute respiratory infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prognostic markers of calcific cardiac valves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intensity of hip pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Serum levels of temocillin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological status
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Area under the time vs. plasma concentration curve from 0 to 240 hr (AUCall)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour average pain score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Geometric Mean Titre Ratio, A/H1N1 Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Geometric Mean Titre Ratio, A/H3N2 Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Geometric Mean Titre Ratio, B Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion, A/H3N2 Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of prosthetic performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasite Clearance Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Relapse rate of P. vivax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of subjects maintaining target hemoglobin range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Aortic valve calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Isometric Peak Torque Quadriceps Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Isokinetic Peak Torque Quadriceps Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Rate of Torque Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Toxicity as assessed by CTCAE 3.0
Endpoint domain: Adverse events/effects
Primary endpoint: Disease Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Splenic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Composite Asthma Severity Index (CASI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation rate to screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: volatile sulfur compound levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients consenting to additional samples
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of research samples collected
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of vaginal delivery <24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of confirmatory diagnoses of malignant lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients reporting adequate relief of dyspeptic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Penn State Worry Questionnaire (PSWQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency and severity of infusion-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Therapeutic misconception cases among participants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time required to release the informed consent signed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Understanding of the possibilities / alternatives to experimental therapy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Comprehension of the significance of the informed consent
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Clinical performance of diagnostic tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline Visual analog scale at eight weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline Boston Questionnaire score at eight weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency and severity of solicited local and systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: fMRI brain response during inhibition to food stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Distribution volume (VT) in the striatum, globus pallidus, and ventral striatum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving hemoglobin level >/=10 g/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Oral mucosal manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement of limb function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Auditory performance skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Requiring Immunosuppressive Therapy After Liver Transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Acute Rejection of Liver Transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Hepatitis C Viral Infection Recurrence After Liver Transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants Who Survived After Liver Transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy of Blood Glucose Level Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall Responder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent-reported Second-hand Smoke Exposure in Cigarettes Per Day From All Sources
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in self-rated health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in satisfaction in ability to manage chronic pain conditions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: User rate of Electronic Partograph
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time required to remain sitting after spinal anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes